Author(s): Parente Lamelas I, Abal Arca J, Frvida Prez JL
Abstract Share this page
Abstract Lung cancer (LC) is a serious health problem due to its high incidence and mortality. Surgery is the most effective therapeutic strategy in this type of tumor, but in recent years new drugs are being investigated that target specific components of the tumor cells, improving survival in patients with advanced disease and relapse. We present a review of individualized treatments in LC, particularly therapies that inhibit epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF) and anaplastic lymphoma kinase (ALK). Copyright © 2011 SEPAR. Published by Elsevier España, S.L. All rights reserved.
This article was published in Arch Bronconeumol
and referenced in Journal of Integrative Oncology